Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University ) Identifier:
First received: November 14, 2011
Last updated: April 10, 2017
Last verified: April 2017
The purpose of this study is to determine whether radiation provided locally to the liver tumor vasculature environment will demonstrate a response of tumor decline. This radiation may cause the tumor cells to die.

Condition Intervention Phase
Stage IV Uveal Melanoma
Device: Sir-Spheres®
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: An Open-Label, Single Institution, Phase II Study Using Radioactive Yttrium90 Microsphere (SIR-Sphere®) in Uveal Melanoma Patients With Hepatic Metastasis

Resource links provided by NLM:

Further study details as provided by Thomas Jefferson University:

Primary Outcome Measures:
  • Clinical benefit rate of previously treated and naive patients [ Time Frame: 3 months post final treatment ]
    Evaluation of clinical benefit includes status of complete and partial response as well as stable disease

  • Number of patients with adverse events [ Time Frame: 3 months post final treatment ]
    Adverse events except for baseline symptoms will be collected from start of first treatment to 3 months post final treatment

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: 2 years post treatment ]
  • Progression Free Survival [ Time Frame: 2 years post treatment ]
    Period of time without progression of liver metastasis

  • Duration of Response [ Time Frame: 2 years post treatment ]

Enrollment: 48
Actual Study Start Date: October 31, 2011
Estimated Study Completion Date: January 1, 2019
Primary Completion Date: February 23, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sirspheres, response evaluation
Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
Device: Sir-Spheres®
Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • must have diagnosis of metastatic melanoma liver disease by histological confirmation
  • one measurable untreated or progressed liver lesion
  • less than 50% liver involvement
  • must have ECOG performance status of 0-1
  • must have adequate renal and bone marrow function as: serum creatinine ≤ 2.0 mg/dl, granulocyte count ≥1000/mm3 and platelet count ≥100,000/mm3
  • must have adequate liver function as: total bilirubin <1.6 mg/ml and albumin >3.0 g/dl

Exclusion Criteria:

  • failure to meet any of the inclusion criteria
  • solitary liver metastasis that is amenable to surgical removal
  • previous treatment with isolated hepatic perfusion
  • systemic chemotherapy within 2 weeks of study entry
  • significant shunting to the lung (>20%) as identified on Technetium-99m-macro-aggregated albumin nuclear medicine break-through scan
  • unsuccessful closure of collateral blood flows from the hepatic artery to non-targeted organs such as the GI tract
  • symptomatic liver failure including ascites and hepatic encephalopathy
  • metastasis outside of liver requiring systemic treatment within 3 months
  • untreated brain metastasis
  • main portal vein occlusion or inadequate collateral flow
  • uncontrolled hypertension or congestive heart failure
  • acute myocardial infarction within 6 months
  • medical complications with implication of less than 6 month survival
  • uncontrolled severe bleeding tendency or active GI bleed
  • significant allergic reaction to iodinated contrast
  • previous radiation that includes the liver in the main radiation field
  • pregnant or breast-feeding women
  • biliary obstruction, stent, or prior biliary surgery including sphincterotomy but excluding cholecystectomy
  • children under the age of 18
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01473004

United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Sidney Kimmel Cancer Center at Thomas Jefferson University
Principal Investigator: Takami Sato, MD Thomas Jefferson University
Principal Investigator: Carin Gonsalves, MD Thomas Jefferson University
  More Information

Additional Information:
Responsible Party: Sidney Kimmel Cancer Center at Thomas Jefferson University Identifier: NCT01473004     History of Changes
Other Study ID Numbers: 10D.95
Study First Received: November 14, 2011
Last Updated: April 10, 2017

Keywords provided by Thomas Jefferson University:
Liver Metastases
Selective internal radiation
Ocular melanoma

Additional relevant MeSH terms:
Uveal Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Eye Neoplasms
Neoplasms by Site
Eye Diseases
Uveal Diseases processed this record on May 22, 2017